Healthcare [ 3/11 ] | Biotechnology [ 34/154 ]
US | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 4, 22 | -0.66
Increased by
0.00%
|
-0.49
Decreased by
-34.69%
|
| Nov 3, 22 | -0.66
Increased by
+2.94%
|
-0.49
Decreased by
-34.69%
|
| Aug 15, 22 | -0.54
Increased by
+28.00%
|
-0.65
Increased by
+16.92%
|
| May 16, 22 | -0.66
Increased by
+12.00%
|
-0.68
Increased by
+2.94%
|
| Mar 28, 22 | -0.66
Increased by
+10.81%
|
-0.61
Decreased by
-8.20%
|
| Nov 15, 21 | -0.68
Increased by
+6.85%
|
-0.80
Increased by
+15.00%
|
| Aug 13, 21 | -0.75
Decreased by
-2.74%
|
-0.63
Decreased by
-19.05%
|
| Aug 12, 21 | -0.75
Decreased by
-27.12%
|
-0.63
Decreased by
-19.05%
|
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 22 | 91.00 K
Decreased by
-85.44%
|
-10.19 M
Decreased by
-4.00%
|
Decreased by
-11.20 K%
Decreased by
-614.30%
|
| Jun 30, 22 | 38.00 K
Decreased by
-95.01%
|
-156.00 K
Increased by
+98.56%
|
Decreased by
-410.53%
Increased by
+71.18%
|
| Mar 31, 22 | 458.00 K
Decreased by
-52.98%
|
-10.03 M
Decreased by
-4.80%
|
Decreased by
-2.19 K%
Decreased by
-122.87%
|
| Dec 31, 21 | 0.00
Decreased by
-100.00%
|
-10.05 M
Decreased by
-6.93%
|
Decreased by
N/A%
Decreased by
N/A%
|
| Sep 30, 21 | 625.00 K
Decreased by
-5.02%
|
-9.80 M
Decreased by
-31.70%
|
Decreased by
-1.57 K%
Decreased by
-38.66%
|
| Jun 30, 21 | 761.00 K
Decreased by
-27.18%
|
-10.84 M
Decreased by
-61.52%
|
Decreased by
-1.42 K%
Decreased by
-121.79%
|
| Mar 31, 21 | 974.00 K
Decreased by
-2.70%
|
-9.57 M
Decreased by
-45.01%
|
Decreased by
-982.34%
Decreased by
-49.03%
|
| Dec 31, 20 | 1.00 M
Increased by
+169.89%
|
-9.40 M
Decreased by
-73.30%
|
Decreased by
-936.06%
Increased by
+35.79%
|
| Rank | ETF | Shares | Market Value | Weight % in ETF |
|---|
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.